Introduction

12
Chronic hepatitis B virus (HBV) infection is an infectious disease 13
that affects approximately two billion people worldwide; in 14 addition, 350 million people are chronic carriers of the virus. 1 
15
Furthermore, the prevalence of hepatitis B surface antigen (HBsAg) 16 positivity among fertile women in some highly epidemic
Q3
areas, 17 such as Africa and Asia, can be as high as 9.2-15.5%, and in China 18 the prevalence is 11.0%. Chronic HBV-infected fertile women may 19 require antiviral treatment during pregnancy.
1-4 20
Telbivudine (L-deoxythymidine; LdT) is an approved oral 21 nucleoside analog (NA) used to inhibit HBV within the cytoplasm 22 that has been assigned to pregnancy category B by the US Food 23 and Drug Administration; therefore, it can be used during 24 pregnancy. For some chronic HBV-infected women who become 25 pregnant during the NA treatment period and for whom 26 conservative treatment is not recommended, discontinuing the 27 antiviral treatment during pregnancy would result in possible 28 exacerbation of hepatic disease and threaten the safety of both the 29 mother and infant. [5] [6] [7] Therefore, NA treatment in these women 30 should be used during pregnancy, either in late pregnancy only or 31 throughout the entire pregnancy. The risk of HBV perinatal 32 transmission is highest in women with high levels of viremia, 8, 9 33 and some pregnant women with a high HBV viral load take an NA 34 to lower the risk of HBV vertical transmission, usually commencing 35 in the third trimester. 10, 11 All of the fetuses in these pregnancies 36 experience intrauterine exposure to the NA, which may affect fetal 37 development. 38 Lamivudine and LdT, as NAs, significantly reduce viral loads 39 and vertical transmission and have favorable safety profiles in 40 pregnancy. [12] [13] [14] [15] [16] [17] [18] However, there are very few reports regarding the 41 growth and development of children prenatally exposed to LdT. 42 The present study aimed to evaluate the growth and development 43 of children exposed to LdT in the fetal period to provide insights 44 into the efficacy and safety of LdT use in the perinatal period. There were no significant differences in the five DQ scores 274 between the early-pregnancy treatment and late-pregnancy 275 treatment groups (p > 0.05) ( Table 4 ). There were also no 276 significant differences in developmental delay between those 277 children prenatally exposed to LdT and the controls (p > 0.05). 278 There were differences in the combined developmental delay and 279 suspicion of developmental delay between those children prena-280 tally exposed to LdT and the controls (p < 0.05) ( Table 5) . 53 infants in our study, with maximum and minimum titers of 289 1000 and 127.21 mIU/l, respectively. The effective vaccination rate of 290 the infants in our study was 98.15% (53/54), with no differences 291 between the early-pregnancy treatment and late-pregnancy treat-292 ment groups (p > 0.05). Only one infant whose parents were both 293 chronic HBV-infected and whose mother had taken LdT throughout 294 her pregnancy was anti-HBs-negative, and the vaccination failed. 295
After enhanced HBV vaccination at age 8 months, the infant's anti-296
HBs titer increased to 127.8 mIU/ml at 12 months of age.
297
Discussion
298
Although there have been a number of studies regarding the 299 safety of LdT treatment in pregnancy, [12] [13] [14] [15] [16] [17] [18] 20 very few have been 300 reported regarding the growth and development of children 301 delivered to chronic HBV-infected women treated with LdT. The 302 abnormality rate in all of the infants in the present study was 303 similar to that of infants born to mothers without or with HBV 304 infection (5.1-6.3% and 7.2-10%, respectively) in previous 305 reports. [21] [22] [23] 306 LdT treatment is reportedly effective for blocking HBV 307 mother-to-infant transmission (MTIT). For infants born to 308 hepatitis B e antigen (HBeAg)-positive mothers, vertical 309 transmission was not blocked in 7-16.3% of women with a 310 high HBV viral load during pregnancy faced with a high risk of 311 MTIT, even after receiving passive-active immunoprophylaxis 312 with hepatitis B immunoglobulin and three doses of hepatitis B 313 vaccine. 24 In a previous study, none of the infants whose 314 mothers received LdT had immunoprophylaxis failure, whereas 315 8.6% of the infants of control mothers did (p = 0.029) in an open-316 label, prospective study of 88 HBeAg-positive pregnant women 317 with chronic HBV infection, HBV DNA levels >6 log 10 copies/ml, 318 and increased levels of alanine aminotransferase.
14 Another 319 study of LdT treatment throughout pregnancy reported that 320 none of 39 of 52 live infants followed up for more than 6 months 321 and who completed all examinations for MTIT were found to 322 have HBsAg positivity, indicating a 100% blocking rate. 15 In the 323 present study, the HBV viral load of the pregnant women who 324 received LdT treatment decreased, whether during their entire 325 pregnancy or late pregnancy, and the HBsAg and HBV DNA of all 326 54 infants were negative, resulting in a 100% HBV MTIT blocking 327 rate. Furthermore, the HBV vaccination was successful in infants 328 exposed to LdT in utero, with 98.15% of the infants protected 329 against hepatitis B and no differences in anti-HBs titer between 330 the infants exposed to LdT throughout the entire pregnancy and 331 those exposed only in late pregnancy. 332 Drug abuse is a primary contributor to birth defects in 333 China. 25 The congenital abnormality rates for infants born 334 to mothers without or with HBV infection are 5.1-6.3% and 335 7.2-10%, respectively. [21] [22] [23] An overall rate of congenital abnor-336 malities of 3.8% (2/53) has been reported in infants whose 337 mothers took LdT for chronic HBV throughout pregnancy. 15 In 338 our study, none of the infants had abnormal hearing, congenital 339 phenylketonuria, or hypothyroidism in follow-up periods lasting 30 In the 375 present study, 84.81% of the overall DQ scores were normal; 376 however in 17 children, the DQ scores suggested either develop-377 mental delay (n = 7) or were suspicious for a developmental delay 378 (n = 10). Abnormally low scores were spread throughout the GDS 379 regions, with no dominant abnormal regions. Moreover, there 380 were no differences between the cases and controls, and the rate of 381 abnormal scores was similar to that (13.1%) in 2330 infants in a 382 previous report. 31 Therefore, the DQs of children delivered to 383 chronic HBV-infected women treated with LdT were normal, 384
suggesting that LdT did not affect the neurodevelopment of these 385 infants. 386
However, the combined developmental delay and suspicious 387 for a developmental delay rates in the present study were higher in 388 the children prenatally exposed to LdT than the controls. Because 389 development activity exists along a continuous spectrum in every 390 child, the final developmental assessment results may be normal 391 for most infants with mildly or moderately delayed development, 392 especially for those with a marginal status. However, intervention 393 and follow-up are necessary when infants exposed to LdT during 394 pregnancy have a lower DQ. Future, larger samples of infants 395 exposed to LdT throughout pregnancy are necessary to discern any 396 differences in DQ. 397
The findings of the present study indicate that the growth and 398 development of children of chronic HBV-infected mothers who are 399 prenatally exposed to LdT are normal, indicating that LdT 400 treatment increases the HBV MTIT blocking rate but does not 401 increase the incidence of congenital abnormalities or affect the 402 physical and neurological development of the infants. LdT 403 treatment during pregnancy in mothers with chronic hepatitis B 404 is safe and effective for infants. However, larger sample sizes are 405 needed in future observations to provide greater insight into the 406 growth and development of children prenatally exposed to NAs, 407 including LdT. 408 Conflict of interest: All authors declare no financial or personal 409 relationships with other people or organizations that could 410 inappropriately influence (bias) their work.
